BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1388 related articles for article (PubMed ID: 12808466)

  • 1. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
    Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good to CU.
    Gu Y; Sundquist WI
    Nature; 2003 Jul; 424(6944):21-2. PubMed ID: 12840737
    [No Abstract]   [Full Text] [Related]  

  • 5. [The innate antiretroviral defense of human cells, based on the DNA editing].
    Pupecka M; Pacak A
    Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
    Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
    J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Sheehy AM; Gaddis NC; Choi JD; Malim MH
    Nature; 2002 Aug; 418(6898):646-50. PubMed ID: 12167863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death and the retrovirus.
    Vartanian JP; Sommer P; Wain-Hobson S
    Trends Mol Med; 2003 Oct; 9(10):409-13. PubMed ID: 14557052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
    Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.